IMMUNOTHERAPY

During a live event, Amit Mahipal, MD, and participants discussed how to recognize and manage immune-related adverse events arising from combination regimens for unresectable HCC.

A PD-1/TIGIT bispecific antibody plus T-DXd yielded pathologic complete responses, avoiding need for further chemotherapy.

A combination regimen targeting LAG-3 and PD-1 did not significantly extend progression-free survival in advanced melanoma vs single-agent pembrolizumab.

Gut microbiome bacteria are linked to risk of recurrence after treatment with immunotherapy for resectable melanoma.

ODD status was granted based on tumor response rates with eftilagimod alfa and pembrolizumab of more than 3-fold above historical benchmarks from radiotherapy alone.

Results of a single-center study showed positive outcomes of reduced-intensity conditioning for tumor-infiltrating lymphocytes in melanoma.

During a live event, Daniel Olson, MD, reviewed a patient case of recurrent melanoma with brain metastases and addressed treatment options.

Experts discuss the SWOG S1512 trial of desmoplastic melanoma and the greater relevance of trials of immunotherapy in rare disease states.

The IMMUNEBOOST-HPV trial investigated whether adding nivolumab (Opdivo) immunotherapy before standard chemoradiation could improve outcomes for patients with high-risk oropharyngeal cancer.

Circulating tumor DNA showed potential as a dynamic biomarker in assessing response to immune checkpoint inhibitors in melanoma.

FDA approves pembrolizumab with chemotherapy for platinum-resistant ovarian cancer, showing significant survival benefits in clinical trials.

A retrospective study of tumor-infiltrating lymphocyte therapy showed that despite its benefit, many patients were unable to receive lifileucel.

Real-world data show over an 40% response rate for lifileucel TIL therapy, indicating that those treated earlier did better and fewer doses of IL-2 could be used effectively.

A groundbreaking phase 2 trial explores a novel, chemotherapy-free immunotherapy for relapsed indolent B-cell lymphomas, aiming to enhance patient outcomes.

The LARA trial reveals promising results for pembrolizumab and lenvatinib in treating recurrent clear cell gynecological cancer, showcasing effective antitumor activity.

Neoadjuvant pembrolizumab showed promising high response rates and melanoma-specific survival outcomes in desmoplastic melanoma.

A large-scale analysis reveals novel predictors of survival and resistance mechanisms in metastatic breast cancer treated with T-DXd, enhancing patient stratification.

The COLIBRI study reveals that neoadjuvant dual immune checkpoint blockade enhances treatment outcomes for locally advanced cervical cancer, showing promising immune responses.

A recent study reveals CAR T-cell therapy patients in Europe experience quality of life comparable to the general population, yet face ongoing physical and mental challenges.

A phase 2 trial reveals elraglusib shows potential benefits in select patients with recurrent salivary gland carcinomas despite missing primary response goals.

Ultrasensitive ctDNA analysis reveals early predictive insights for immunotherapy outcomes in advanced solid tumors, enhancing patient management and survival predictions.

PLT012, a groundbreaking anti-CD36 antibody, enters clinical trials to enhance immune responses in solid tumors, promising new hope for cancer treatment.

FDA fast-tracks muzastotug and pembrolizumab for metastatic colorectal cancer, showcasing promising efficacy and safety in early studies.

Inaregacestat shows promising results in treating desmoid tumors, significantly improving progression-free survival and reducing tumor volume in recent trials.

FDA approves liso-cel, the first CAR T-cell therapy for relapsed marginal zone lymphoma, offering hope for improved patient outcomes.